Marinus Pharmaceuticals ganaxolone was granted FDA orphan designation as a treatment of Lennox-Gastaut Syndrome, or LGS, according to a post to the agency’s website. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNS:
- Marinus Pharmaceuticals names Steven Pfanstiel COO
- Marinus sees FY23 ZTALMY U.S. net product revenue $15M-$17M
- Marinus Pharmaceuticals reports Q4 EPS (76c), consensus (70c)
- Marinus Pharmaceuticals options imply 12.7% move in share price post-earnings
- Billionaire Steve Cohen Pulls the Trigger on These 2 ‘Strong Buy’ Stocks